MM1OAEA02
OPEN TO ACCRUAL
Ph II Study of Venetoclax+HMA-Based Therapies for Txt of Older+Unfit Adults with ND FLT3-AML
MM1YAS01
OPEN TO ACCRUAL
Ph II Study Comparing Cy,Dauno vs Cy,Dauno,Ven - Aza,Ven - Liposome - Liposome,Ven in High-Risk AML
MYELOMATCH
OPEN TO ACCRUAL
Master Screening Protocol for Tier Advancement in the NCI myeloMATCH Trials
UW19086
OPEN TO ACCRUAL
LTFU Protocol for Subjects Treated with Gene-Modified T Cells
UW23093
OPEN TO ACCRUAL
Ph 1 Study of Ven and Aza, Ven, 7+3 or 7+3+quizartinib in combo with Ko-539 in AML
UW23129
OPEN TO ACCRUAL
Ph1 Dose-Escalation Trial of Mesenchymal Stromal Cells in pts w Medical Xerostomia
UW24056
OPEN TO ACCRUAL
PH1 and 1b Study of CLK Inhibitor BH-30236 in Adults with R,R AML or HR-MDS
UW25034
OPEN TO ACCRUAL
Ph I Study of PPx TCRaB+ and CD19+ Depleted DLI after allo-SCT in High-Risk Pts with HM
UW25094
OPEN TO ACCRUAL
Ph 3 Blinded Study of Ziftomenib in Combo w Ven+Aza or 7+3 in Pts w Untreated NPM1-m or KMT2A-r AML
UW25132
OPEN TO ACCRUAL
Post-Transplant Cyclophosphamide-based GVHD Prophylaxis in Pts under MUD PBSCT - ACCELERATE
UW25142
OPEN TO ACCRUAL
A Ph 3 Study of Sonrotoclax Plus Zanubrutinib vs. Placebo Plus Zanubrutinib in Pts with R,R MCL